GlassScriptPhysician profile
Colleen E Farley
NPI 1295780468
$1,458.22
in general payments reported to CMS, 2019-2025
29 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $292 · 2022: $19.01 · 2023: $212 · 2024: $602 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.31 |
| Education | $116.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $217.08 | 2021-2024 | Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $162.37 | 2021-2025 | Opdivo, Augtyro, Opdualag |
| Celgene Corporation | $125.23 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Gilead Sciences, INC. | $84.08 | 2023-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $69.12 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Sobi, INC | $67.19 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $66.86 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $51.11 | 2022-2024 | Somatuline Depot, Onivyde |
| Merck Sharp & Dohme LLC | $48.74 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Tersera Therapeutics LLC | $34.91 | 2024 | Zoladex |
| Genzyme Corporation | $34.22 | 2024 | |
| Abbvie INC. | $34.19 | 2024-2025 | |
| Pfizer INC. | $33.64 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.42 | 2025 | |
| Beigene USA, INC. | $29.94 | 2024 | Brukinsa |
| Taiho Oncology, INC. | $28.04 | 2025 | |
| Geron Corporation | $24.08 | 2024 | Rytelo |
| Deciphera Pharmaceuticals INC. | $21.59 | 2023 | Qinlock |
| Medtronic, INC. | $20.58 | 2023 | Osteocool Rf Ablation System |
| Tempus Ai, INC | $19.28 | 2024 | |
| Mirati Therapeutics, INC. | $19.03 | 2023 | Krazati |
| Alexion Pharmaceuticals, INC. | $17.96 | 2025 | Ultomiris |
| Glaxosmithkline, LLC. | $16.23 | 2023 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $15.97 | 2023 | Imbruvica, Epkinly |
| Novocure INC. | $14.64 | 2023 | Optune |
| Pharmaessentia USA Corporation | $14.44 | 2024 | Besremi |
| Genentech USA, INC. | $14.29 | 2025 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Farley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.